Clinical trial · Interventional
Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors
Phase Ⅱ Study of Concurrent Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors
NCT02636556CI-TRIAL-00043270completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is designed to evaluate the feasibility and safety of concurrent chemoradiotherapy for limited advanced unresectable thymoma or thymic carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thymoma and Thymic Carcinoma | Thymoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| concurrent chemoradiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- chemoradiation
- description
- concurrent chemoradiation.
- interventionNames
- Radiation: concurrent chemoradiation
Primary outcomes (1)
- measure
- Objective response rate
- timeFrame
- 3 months after treatment
- description
- Evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria
Secondary outcomes (3)
- measure
- Overall survival
- timeFrame
- 2 years
- description
- from registration to death as a result of any cause.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1.18\~75 years old; 2.Eastern Cooperative Oncology Group performance status of 0 to 2; 3.Pathologically or cytologically confirmed untreated thymoma or thymic carcinoma; 4.Unresectable, limited adanced disease could be encompassed within a tolerable radiotherapy field; 5.Have adequate bone marrow, hepatic, and renal function; 6.Patients who cannot receive surgery resection; 7.Written informed consent. Exclusion Criteria: 1. Distant metastases could not be encompassed within a tolerable radiotherapy field; 2. Underwent surgery, radiotherapy or chemotherapy before entering this study ; 3. Have other malignancy history excluding carcinoma in situ of cervix in the previous five years; 4. Active clinical pulmonary infection; 5. Pregnant or nursing.
References
Publications (0)
Data not yet available
No reference posted for this study.